{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:24:55Z","timestamp":1794979495977,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Division of Gastroenterology, University of California, San Francisco"},{"name":"Bakar Computational Health Sciences Institute, University of California, San Francisco"},{"DOI":"10.13039\/100008913","name":"University of San Francisco","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008913","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The advent of clinical trial data sharing platforms has created opportunities for making new discoveries and answering important questions using already collected data. However, existing methods for meta-analyzing these data require the presence of shared control groups across studies, significantly limiting the number of questions that can be confidently addressed. We sought to develop a method for meta-analyzing potentially heterogeneous clinical trials even in the absence of a common control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This work was conducted within the context of a broader effort to study comparative efficacy in Crohn\u2019s disease. Following a search of clnicaltrials.gov we obtained access to the individual participant data from nine trials of FDA-approved treatments in Crohn\u2019s Disease (<jats:italic>N<\/jats:italic>\u2009=\u20093392). We developed a method involving sequences of regression and simulation to separately model the placebo- and drug-attributable effects, and to simulate head-to-head trials against an appropriately normalized background. We validated this method by comparing the outcome of a simulated trial comparing the efficacies of adalimumab and ustekinumab against the recently published results of SEAVUE, an actual head-to-head trial of these drugs. This study was pre-registered on PROSPERO (#157,827) prior to the completion of SEAVUE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Using our method of sequential regression and simulation, we compared the week eight outcomes of two virtual cohorts subject to the same patient selection criteria as SEAVUE and treated with adalimumab or ustekinumab. Our primary analysis replicated the corresponding published results from SEAVUE (<jats:italic>p<\/jats:italic>\u2009=\u20090.9). This finding proved stable under multiple sensitivity analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This new method may help reduce the bias of individual participant data meta-analyses, expand the scope of what can be learned from these already-collected data, and reduce the costs of obtaining high-quality evidence to guide patient care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-023-02020-5","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:02:20Z","timestamp":1696330940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sequential regression and simulation: a method for estimating causal effects from heterogeneous clinical trials without a common control group"],"prefix":"10.1186","volume":"23","author":[{"given":"Vivek A.","family":"Rudrapatna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh G.","family":"Ravindranath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas V.","family":"Arneson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Mosenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul J.","family":"Butte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"2020_CR1","doi-asserted-by":"crossref","unstructured":"Chalmers I. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci. 1993; 703: 156\u201363; discussion 163\u20135.","DOI":"10.1111\/j.1749-6632.1993.tb26345.x"},{"key":"2020_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001855","volume":"12","author":"JF Tierney","year":"2015","unstructured":"Tierney JF, Vale C, Riley R, et al. Individual Participant Data (IPD) Meta-analyses of randomised controlled trials: guidance on their use. PLoS Med. 2015;12: e1001855.","journal-title":"PLoS Med"},{"key":"2020_CR3","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1002\/sim.5764","volume":"32","author":"S Schmitz","year":"2013","unstructured":"Schmitz S, Adams R, Walsh C. Incorporating data from various trial designs into a mixed treatment comparison model. Stat Med. 2013;32:2935\u201349.","journal-title":"Stat Med"},{"key":"2020_CR4","first-page":"46","volume":"15","author":"JG Ibrahim","year":"2000","unstructured":"Ibrahim JG, Chen M-H. Power prior distributions for regression models. Stat Sci. 2000;15:46\u201360.","journal-title":"Stat Sci"},{"key":"2020_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1177\/0962280218754928","volume":"28","author":"J Zhang","year":"2019","unstructured":"Zhang J, Ko C-W, Nie L, Chen Y, Tiwari R. Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies. Stat Methods Med Res. 2019;28:1293\u2013310.","journal-title":"Stat Methods Med Res"},{"key":"2020_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/10543406.2021.1895190","volume":"31","author":"L Thompson","year":"2021","unstructured":"Thompson L, Chu J, Xu J, Li X, Nair R, Tiwari R. Dynamic borrowing from a single prior data source using the conditional power prior. J Biopharm Stat. 2021;31:403\u201324.","journal-title":"J Biopharm Stat"},{"key":"2020_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/10543406.2019.1657133","volume":"29","author":"C Wang","year":"2019","unstructured":"Wang C, Li H, Chen W-C, et al. Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies. J Biopharm Stat. 2019;29:731\u201348.","journal-title":"J Biopharm Stat"},{"key":"2020_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/19466315.2019.1654913","volume":"12","author":"X Li","year":"2020","unstructured":"Li X, Song Y. Target population statistical inference with data integration across multiple sources\u2014an approach to mitigate information shortage in rare disease clinical trials. Stat Biopharm Res. 2020;12:322\u201333.","journal-title":"Stat Biopharm Res"},{"key":"2020_CR9","doi-asserted-by":"crossref","unstructured":"Li X, Miao W, Lu F, Zhou X. Improving efficiency of inference in clinical trials with external control data. Biometrics. 2021; biom.13583.","DOI":"10.1111\/biom.13583"},{"key":"2020_CR10","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet Lond Engl. 2022;399:2200\u201311.","journal-title":"Lancet Lond Engl"},{"key":"2020_CR11","unstructured":"PROSPERO | Comparative effectiveness of treatments for moderate-to-severe Crohn\u2019s disease: an individual participant data meta-analysis. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=157827Accessed 28 Sept 2021."},{"key":"2020_CR12","unstructured":"The YODA Project | 2018\u20133476. Effic. Crohn\u2019s Dis. Treat. Stratif. Dis. Phenotype. https:\/\/yoda.yale.edu\/data-request\/2018-3476 . Accessed\u00a0 28 Sept 2021."},{"key":"2020_CR13","unstructured":"Efficacy of Crohn\u2019s Disease Treatment Stratified by Disease Phenotype. Vivli. https:\/\/vivli.org\/efficacy-of-crohns-disease-treatment-stratified-by-disease-phenotype-2\/ . Accessed\u00a0 28 Sept 2021."},{"key":"2020_CR14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMhle1309073","volume":"369","author":"MM Mello","year":"2013","unstructured":"Mello MM, Francer JK, Wilenzick M, Teden P, Bierer BE, Barnes M. Preparing for Responsible Sharing of Clinical Trial Data. N Engl J Med. 2013;369:1651\u20138.","journal-title":"N Engl J Med"},{"key":"2020_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k510","volume":"360","author":"M Packer","year":"2018","unstructured":"Packer M. Data sharing in medical research. BMJ. 2018;360: k510.","journal-title":"BMJ"},{"key":"2020_CR16","unstructured":"Health Data Sharing Special Publication. Natl. Acad. Med. https:\/\/nam.edu\/health-data-sharing-special-publication\/ . Accessed 10 Aug 2022."},{"key":"2020_CR17","unstructured":"Examination of Clinical Trial Costs and Barriers for Drug Development. ASPE. https:\/\/aspe.hhs.gov\/reports\/examination-clinical-trial-costs-barriers-drug-development-0 . Accessed 12 June 2022."}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-023-02020-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-023-02020-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-023-02020-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T15:16:05Z","timestamp":1700234165000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-023-02020-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1186\/s12874-023-02020-5","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"23 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved in accordance with the Declaration of Helsinki and with the oversight of the UCSF IRB (#18\u201324588). This review board waived the need for participant consent given that the underlying data had already been deidentified by the owners of the raw data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VAR received grant support from Janssen Inc and Alnylam Inc for unrelated work during this study. DVA is currently an employee at Bristol Myers Squibb. AJB is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and in the recent past, Samsung, 10\u2009\u00d7\u2009Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet (Google), Microsoft, Amazon, Snap, 10\u2009\u00d7\u2009Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. Atul Butte receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. Atul Butte\u2019s research has been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor\u2019s Office of Planning and Research, California Institute for Regenerative Medicine, L\u2019Oreal, and Progenity. The authors have declared that no actual competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}